Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited
Key Takeaways
- Tirzepatide is a dual GLP-1 and GIP receptor agonist, not a pure GLP-1 RA
- It is the active ingredient in Mounjaro (type 2 diabetes) and Zepbound (chronic weight management and OSA)
- The dual mechanism produces larger weight loss than pure GLP-1 RAs like semaglutide in head-to-head trials
- Tirzepatide is sometimes called a "twincretin" because it activates two incretin receptors simultaneously
- Compounded tirzepatide is not FDA-approved and is not equivalent to Mounjaro or Zepbound
Direct answer
Tirzepatide activates the GLP-1 receptor, so calling it a "GLP-1" in casual conversation is not wrong. Technically, it is a dual GLP-1 and GIP receptor agonist, which makes it a different sub-class of incretin mimetic. The distinction matters because the dual mechanism produces larger clinical effects than pure GLP-1 medications. The cleanest answer: tirzepatide is in the broader incretin agonist family and shares mechanism with GLP-1 drugs, but it is not exclusively a GLP-1.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The pharmacology answer in plain terms
- What tirzepatide is, structurally
- How the dual receptor mechanism works
- The brand products: Mounjaro and Zepbound
- Tirzepatide vs semaglutide head-to-head
- Where tirzepatide came from
- The SURPASS and SURMOUNT trial programs
- Side effects and contraindications
- The compounded tirzepatide question
- Future directions: triple agonists and beyond
- Contrary view: does the class distinction matter clinically?
- Decision framework
- FAQ
- Sources
The pharmacology answer in plain terms
Drug classes are organized by mechanism of action. The class of pure GLP-1 receptor agonists includes semaglutide, liraglutide, exenatide, dulaglutide, and lixisenatide. All of these molecules activate one receptor: the GLP-1 receptor.
Tirzepatide does something different. The molecule was engineered specifically to bind two receptors: the GLP-1 receptor and the GIP receptor. Both receptors are part of the incretin system, which coordinates the body's response to meals. Activating both simultaneously appears to produce stronger metabolic effects than activating either alone.
The cleanest pharmacology label for tirzepatide is "dual GIP and GLP-1 receptor agonist." The FDA prescribing information uses this language. Some review articles call it a "twincretin" or "dual incretin agonist." All of these terms describe the same drug.
Calling tirzepatide "a GLP-1" is partially correct because the GLP-1 receptor is involved. It is just not the complete description. Patients and clinicians often use the shorter label for convenience.
What tirzepatide is, structurally
Tirzepatide is a 39 amino acid synthetic peptide. The sequence was designed to bind both receptor targets with high affinity. The molecule carries a C20 fatty diacid side chain attached via a linker, similar in concept to the modifications used in semaglutide and other long-acting incretin agonists.
The fatty acid chain serves three purposes:
- Albumin binding. The chain binds reversibly to albumin in the blood, slowing renal clearance.
- DPP-4 resistance. The amino acid substitutions in the active site block the enzyme that destroys native incretin hormones.
- Receptor presentation. The overall conformation supports binding to both GLP-1 and GIP receptors.
The half-life in humans is about 5 days. This supports once-weekly dosing. Steady state is reached after about 4 weekly doses.
The receptor affinity profile is interesting. Tirzepatide binds the GIP receptor with affinity comparable to native human GIP. It binds the GLP-1 receptor with affinity lower than native human GLP-1, sometimes described as "imbalanced" or "biased" toward GIP. The functional implications of this bias remain an active research area.
How the dual receptor mechanism works
Both GLP-1 and GIP are incretin hormones released by the gut after meals. GLP-1 comes from L-cells in the distal small intestine and colon. GIP comes from K-cells in the upper small intestine, primarily the duodenum and proximal jejunum. Both stimulate insulin release in a glucose-dependent manner.
The receptors for these hormones are expressed in different patterns:
- GLP-1 receptors: pancreas (beta cells, alpha cells), stomach, intestine, hypothalamus, brainstem, heart, kidney
- GIP receptors: pancreas (beta cells), adipose tissue, central nervous system, bone
The overlap is substantial in the pancreas, where both receptors enhance insulin secretion. The differences are notable in adipose tissue (GIP receptors are more prominent) and in the brain (both, but distinct patterns).
When tirzepatide activates both receptors, the clinical result is lower blood glucose, reduced appetite, slowed gastric emptying, and weight loss. Whether the additional benefit over pure GLP-1 RAs comes from GIP-specific actions, from dual receptor occupancy in shared tissues, or from some other property of the molecule is debated.
The brand products: Mounjaro and Zepbound
Eli Lilly markets tirzepatide as two distinct products:
- Mounjaro (approved May 2022). FDA indication: type 2 diabetes. Dose range: 2.5 mg starting, then 5 to 15 mg weekly.
- Zepbound (approved November 2023, with OSA added December 2024). FDA indication: chronic weight management; obstructive sleep apnea in adults with obesity. Dose range: 2.5 mg starting, then 5 to 15 mg weekly.
The active ingredient is the same molecule in both products. The differentiation is regulatory and commercial: separate clinical trial programs, separate FDA approval pathways, separate insurance billing, separate pen designs.
A patient on Mounjaro and a patient on Zepbound at the same dose are receiving the same amount of the same molecule. The labels and the prior-authorization criteria differ.
Tirzepatide vs semaglutide head-to-head
SURPASS-2 (Frias et al., New England Journal of Medicine 2021) directly compared tirzepatide and semaglutide in adults with type 2 diabetes:
| Treatment | HbA1c reduction (40 weeks) | Weight loss |
|---|---|---|
| Tirzepatide 5 mg | 2.01% | 7.6 kg |
| Tirzepatide 10 mg | 2.24% | 9.3 kg |
| Tirzepatide 15 mg | 2.30% | 11.2 kg |
| Semaglutide 1.0 mg | 1.86% | 5.7 kg |
The differences favored tirzepatide at every dose. The 15 mg dose produced roughly twice the weight loss of semaglutide 1.0 mg.
SURMOUNT-5, a direct head-to-head trial in adults with obesity without diabetes, compared tirzepatide to semaglutide 2.4 mg (the Wegovy dose). Tirzepatide produced significantly more weight loss. The result confirmed what cross-trial comparison between SURMOUNT-1 (tirzepatide) and STEP 1 (semaglutide) had suggested.
For most patients who could tolerate either drug, tirzepatide produces larger effects on glucose and body weight. Whether that translates to better long-term clinical outcomes (cardiovascular events, mortality) is still being studied. The SURPASS-CVOT trial reported initial cardiovascular results in 2024-2025; final labeling decisions were ongoing as of May 2026.
Where tirzepatide came from
The dual agonist concept emerged from research on incretin biology in the 2000s and 2010s. Scientists at Eli Lilly and elsewhere had been working on GIP receptor agonists, GLP-1 receptor agonists, and glucagon receptor agonists, often with disappointing standalone results. Combining receptors offered theoretical advantages.
The decisive paper was Coskun et al. (Molecular Metabolism 2018), describing LY3298176 (the development code for tirzepatide) as a novel dual GIP and GLP-1 receptor agonist. The molecule entered Phase 1 trials shortly afterward. Phase 2 and Phase 3 results consistently exceeded expectations based on extrapolation from pure GLP-1 RAs.
The clinical program (SURPASS for diabetes, SURMOUNT for obesity) reported between 2020 and 2024. The unexpectedly large weight loss in non-diabetic populations during SURMOUNT-1 was particularly striking and helped accelerate the obesity approval.
Lotte Bjerre Knudsen, who had led the development of liraglutide and semaglutide at Novo Nordisk, was a major figure in pure GLP-1 RA development. Tirzepatide came from a different lineage, with Lilly's incretin research team building on years of dual-agonist work.
The SURPASS and SURMOUNT trial programs
SURPASS (for diabetes) included:
- SURPASS-1: monotherapy vs placebo
- SURPASS-2: vs semaglutide
- SURPASS-3: vs insulin degludec
- SURPASS-4: vs insulin glargine in high-CV-risk patients
- SURPASS-5: add-on to insulin glargine
- SURPASS-CVOT: cardiovascular outcomes
SURMOUNT (for obesity) included:
- SURMOUNT-1: in adults with obesity
- SURMOUNT-2: in adults with obesity and type 2 diabetes
- SURMOUNT-3: after intensive lifestyle intervention
- SURMOUNT-4: maintenance withdrawal trial
- SURMOUNT-5: direct head-to-head vs semaglutide for obesity
- SURMOUNT-OSA: in adults with obesity and obstructive sleep apnea
Across both programs, tirzepatide consistently produced larger metabolic effects than placebo, larger effects than active comparators where tested, and dose-dependent improvements in primary endpoints.
Side effects and contraindications
The side-effect profile of tirzepatide is similar to pure GLP-1 RAs. Gastrointestinal effects dominate the adverse-event picture:
- Nausea: 28-31 percent at obesity doses (SURMOUNT-1)
- Diarrhea: 19-23 percent
- Vomiting: 9-12 percent
- Constipation: 11-17 percent
- Abdominal pain: 8-10 percent
Most events are mild to moderate and improve as patients adjust to higher doses. The titration schedule is designed to minimize peak severity.
Tirzepatide carries a boxed warning for medullary thyroid carcinoma, based on rodent data showing thyroid C-cell tumors. It is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
Other labeled warnings: acute pancreatitis, acute gallbladder disease, severe gastrointestinal adverse reactions, acute kidney injury (typically from dehydration), hypoglycemia (when combined with insulin or sulfonylureas), hypersensitivity reactions, diabetic retinopathy complications, suicidal behavior and ideation (monitoring recommended), and pulmonary aspiration during anesthesia (consider perioperative discontinuation).
The compounded tirzepatide question
Tirzepatide was on the FDA drug shortage list from December 2022 to October 2024. During the shortage, 503A compounding pharmacies could prepare compounded tirzepatide for individual patients. Telehealth platforms expanded rapidly to provide access.
When the shortage was declared resolved in October 2024, the shortage-based compounding pathway ended. A federal court briefly delayed enforcement (the Outsourcing Facilities Association vs FDA case), but the FDA position prevailed by early 2025.
Compounded tirzepatide still exists through 503A personalized prescribing for specific clinical situations, but at much lower volume than during 2023-2024. Compounded preparations are not FDA-approved and are not equivalent to Mounjaro or Zepbound. The active ingredient is the same molecule, but the manufacturing process, quality controls, and regulatory review are different.
FormBlends works with state-licensed 503A compounding pharmacies and provides compounded options where clinically appropriate and legally permitted under current regulations. Compounded products are not substitutes for FDA-approved medications.
Future directions: triple agonists and beyond
The dual-agonist concept that produced tirzepatide is being extended in two directions.
Triple agonists. Retatrutide, developed by Eli Lilly, activates the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Phase 2 data (Jastreboff et al., New England Journal of Medicine 2023) reported about 24 percent weight loss at 48 weeks on the highest dose. Phase 3 trials are ongoing. Retatrutide is investigational and not FDA-approved. FormBlends does not sell or supply retatrutide.
Combination products. Cagrisema combines semaglutide with cagrilintide (an amylin analog). Other combinations are in development. Cagrisema is investigational and not FDA-approved. FormBlends does not sell or supply cagrisema or cagrilintide.
Oral small molecules. Orforglipron is a non-peptide oral GLP-1 RA in Phase 3 development. The investigational drug is not FDA-approved. FormBlends does not sell or supply orforglipron.
These pipeline drugs may eventually surpass tirzepatide on efficacy metrics, but as of May 2026 tirzepatide remains the most effective FDA-approved obesity medication.
Contrary view: does the class distinction matter clinically?
The pharmacology distinction between pure GLP-1 RAs and dual agonists is real. Whether it matters in everyday clinical practice is debatable.
Arguments that the distinction matters:
- Tirzepatide produces measurably larger weight loss than semaglutide. Patients deserve to know this when choosing between options.
- The dual mechanism may produce different long-term outcomes, including potentially different cardiovascular effects.
- Future drugs in the dual or triple agonist space will look more like tirzepatide than like pure GLP-1 RAs. The framework is important for understanding the pipeline.
Arguments that the distinction is overstated:
- The patient experience overlaps almost completely: weekly injection, similar GI side effects, similar weight-loss trajectory.
- The decision between tirzepatide and semaglutide rarely comes down to receptor pharmacology; insurance coverage and individual tolerance usually dominate.
- Many clinicians effectively manage both drugs as if they were one class, with adjustments for the different magnitude of effect.
The reasonable middle position: the distinction is real and matters for understanding mechanism, comparing efficacy, and tracking the pipeline. For most prescribing decisions, the practical considerations (coverage, tolerability, individual response) matter more than the receptor-level pharmacology.
Decision framework
If you are asking whether tirzepatide is a GLP-1 in casual conversation:
- The casual answer is yes; the precise answer is "dual GLP-1/GIP agonist."
- Either answer can be appropriate depending on context.
If you are choosing between tirzepatide and semaglutide:
- Tirzepatide produces larger metabolic effects in clinical trials.
- Both drugs have similar side-effect profiles and dosing schedules.
- Insurance coverage, individual tolerance, and specific clinical context drive most decisions.
If you are taking tirzepatide and want to understand it better:
- You are on a dual incretin agonist, not a pure GLP-1 medication.
- The GLP-1 component is real; the GIP component is part of why the drug is more effective than pure GLP-1 RAs.
- Side effects and monitoring follow the GLP-1 RA template closely.
If you are considering compounded tirzepatide:
- Compounded tirzepatide is not FDA-approved and is not Mounjaro or Zepbound.
- The compounding shortage pathway ended in October 2024; current compounding is restricted to 503A personalized prescribing.
- Discuss the clinical reasoning with your provider before pursuing compounded therapy.
FAQ
Is tirzepatide a GLP-1? Tirzepatide activates the GLP-1 receptor but is a dual GLP-1/GIP receptor agonist, not a pure GLP-1 RA. Casual yes; precise no.
What is tirzepatide? A 39 amino acid synthetic peptide that binds both the GLP-1 and GIP receptors. Developed by Eli Lilly. Active ingredient in Mounjaro and Zepbound.
How is tirzepatide different from semaglutide? Semaglutide is pure GLP-1. Tirzepatide is dual GLP-1/GIP. Tirzepatide produces larger weight loss and stronger glycemic effects in head-to-head trials.
What does tirzepatide do in the body? Activates incretin receptors in the pancreas, gut, and brain. Lowers glucose, reduces appetite, slows gastric emptying.
How much weight do people lose on tirzepatide? SURMOUNT-1: about 22.5 percent at 15 mg over 72 weeks. Individual results vary.
Is tirzepatide FDA-approved? Yes. As Mounjaro for type 2 diabetes (2022) and as Zepbound for chronic weight management (2023) and OSA in adults with obesity (2024).
Is compounded tirzepatide the same as Mounjaro or Zepbound? No. Compounded tirzepatide is not FDA-approved. It uses the same active ingredient but is prepared by 503A pharmacies under individual prescriptions.
Why do people call tirzepatide a GLP-1 if it isn't one? The drug activates the GLP-1 receptor, the experience overlaps with pure GLP-1 RAs, and the shorthand is convenient. Specialists distinguish dual agonists when precision matters.
Who makes tirzepatide? Eli Lilly and Company. The same manufacturer also makes Trulicity (dulaglutide), a pure GLP-1 RA.
What was the development code for tirzepatide? LY3298176. The first major publication on the molecule was Coskun et al. in Molecular Metabolism (2018).
Does tirzepatide work in patients without diabetes? Yes. SURMOUNT-1 enrolled adults with obesity without diabetes and showed substantial weight loss.
What is a twincretin? Informal term for a drug that mimics two incretin hormones at once. Tirzepatide is the prototypical twincretin.
Sources
- FDA Prescribing Information. Mounjaro (tirzepatide). Updated 2024.
- FDA Prescribing Information. Zepbound (tirzepatide). Updated 2024.
- Coskun T et al. LY3298176, a Novel Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus. Molecular Metabolism. 2018.
- Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024.
- Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea (SURMOUNT-OSA). New England Journal of Medicine. 2024.
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2). New England Journal of Medicine. 2023.
- Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide (SURPASS-1). Lancet. 2021.
- FDA Drug Shortages Database. Tirzepatide Injection. 2022-2024.
- American Diabetes Association. Standards of Medical Care in Diabetes. 2025.
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018.
Footer disclaimers
Platform Disclaimer. FormBlends is a telehealth platform that facilitates connections between patients and independent licensed providers and U.S.-based pharmacies. We are not a pharmacy and do not provide direct clinical care. Treatment decisions rest with the prescribing clinician.
Compounded Medication Notice. Compounded tirzepatide is distinct from Mounjaro and Zepbound. State-licensed 503A pharmacies prepare compounded preparations in response to individual prescriptions. The FDA has not reviewed compounded preparations for purity, potency, sterility, or stability. Compounded tirzepatide is not FDA-approved.
Results Disclaimer. Trial averages reflect controlled study conditions. Real-world outcomes depend on adherence, dose tolerated, dietary habits, activity levels, and individual biology. Discontinuation typically results in weight regain.
Trademark Notice. Mounjaro, Zepbound, and Trulicity are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, Rybelsus, Saxenda, and Victoza are registered trademarks of Novo Nordisk A/S. Byetta and Bydureon are registered trademarks of AstraZeneca. FormBlends has no affiliation with Eli Lilly, Novo Nordisk, AstraZeneca, or any other listed manufacturer.